Zevra Therapeutics Appoints New Officers, Reports Q3 Loss

TL;DR

Zevra brings in new execs, reports $15.9M Q3 loss, and partners with NINDS on AZ-002.

AI Summary

On December 2, 2024, Zevra Therapeutics, Inc. announced the appointment of Dr. Michael L. Smith as Chief Medical Officer and Dr. David M. Reif as Chief Scientific Officer. The company also disclosed its financial results for the third quarter ended September 30, 2024, reporting a net loss of $15.9 million. Additionally, Zevra Therapeutics entered into a strategic collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) to advance its drug candidate, AZ-002.

Why It Matters

The appointment of new key scientific and medical officers signals a potential shift in the company's R&D strategy, while the collaboration with NINDS could accelerate the development of its drug candidate.

Risk Assessment

Risk Level: medium — The company reported a significant net loss in Q3 and is undergoing leadership changes, indicating potential operational and strategic uncertainties.

Key Numbers

• $15.9M — Q3 2024 Net Loss (Indicates ongoing operational expenses exceeding revenue.)
• December 2, 2024 — Report Date (Date of the earliest event reported in the 8-K.)

Key Players & Entities

• Zevra Therapeutics, Inc. (company) — Registrant
• Dr. Michael L. Smith (person) — Appointed Chief Medical Officer
• Dr. David M. Reif (person) — Appointed Chief Scientific Officer
• $15.9 million (dollar_amount) — Net loss for Q3 2024
• September 30, 2024 (date) — End of Q3 2024
• National Institute of Neurological Disorders and Stroke (NINDS) (company) — Collaboration partner
• AZ-002 (drug_candidate) — Subject of collaboration

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock , par value $0.0001 per share ZVRA The Nasdaq Stock Mark

Filing Documents

• zvra20241204_8k.htm (8-K) — 32KB
• ex_754699.htm (EX-99.1) — 11KB
• picture3.jpg (GRAPHIC) — 6KB
• 0001437749-24-036876.txt ( ) — 189KB
• zvra-20241202.xsd (EX-101.SCH) — 3KB
• zvra-20241202_def.xml (EX-101.DEF) — 12KB
• zvra-20241202_lab.xml (EX-101.LAB) — 15KB
• zvra-20241202_pre.xml (EX-101.PRE) — 12KB
• zvra20241204_8k_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On December 6, 2024, Zevra Therapeutics, Inc., a Delaware corporation (the "Company"), issued a press release announcing the matters disclosed in this report. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated December 6, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Zevra Therapeutics, Inc . Date: December 6, 2024 By: /s/ Timothy J. Sangiovanni Timothy J. Sangiovanni, CPA Senior Vice President, Finance and Corporate Controller

View Full Filing

View this 8-K filing on SEC EDGAR